In order to compare the efficacy and side effects of Cefmetazole (CS-1170) with those of cefazolin (CEZ), a comparative clinical trial has been carried out upon respiratory tract infections at 38 ...institutions all over the country by means of a double blind method. CS-1170 as well as CEZ were intravenously drip-infused twice a day for 14 days at a daily dose of 4g to 238 patients with acute or chronic respiratory tract infections. A statistical analysis between the two drugs was made on the efficacy in 176 cases, excluding the cases departing from rules of the protocol, and on side effects in 231 cases excluding the cases which infringed rules of the protocol. Furthermore, a statistical analysis between the two drugs was also made on the efficacy and side effects in almost all cases according to the judgement by doctors in charge. The conclusions obtained were as follows; 1) The clinical efficacy of a daily 4g of CS-1170 was significantly superior to that of CEZ in the treatment of respiratory tract infections. 2) Regarding the degree of improvement in body temperature on the 3 rd day and in volume of sputum on the 14 th day, the group treated with CS-1170 was significantly superior to the group treated with CEZ in pneumonia and lung abscess. In addition, regarding the degree of improvement in cough on the 3 rd day, the group treated with CS-1170 was significantly superior to the group treated with CEZ in the diseases other than pneumonia and lung abscess. 3) No significance was observed in the occurrence of side effects in both groups. 4) The clinical utility of CS-1170 was significantly superior to that of CEZ.
In order to compare the efficacy and side effects of Bacampicillin (BAPC) with those of Amoxicillin (AMPC), a comparative clincal trial has been carried out upon pneumonia at 35 institutions all over ...the country by means of a double-blind method. BAPC and AMPC were orally administered to 153 patients with pneumonia at a daily dose of 1g for 14 days. A statistical analysis between the two drugs was made on the efficacy in 116 cases excluding the cases which deviated rules of the protocol and on side effects in 147 cases excluding the cases which deviated rules of the protocol. Furthermore, a statistical analysis between the two drugs was also made on the efficacy, side effects, and utility in almost all cases according to the judgement by doctors in charge. The results are as follows: 1) The clinical efficacy of BAPC at the daily dose of 1g was equal to that of AMPC in the treatment of pneumonia. 2) Regarding the degree of improvement of symptoms and laboratory test data, no significant difference was observed between the two groups except for the superiority of AMPC over BAPC in tne degree of improvement in CRP at the end of treatment. 3) No significant difference was observed between both groups in the occurrence of side effects.
PDF
